BACKGROUND & AIMS: Liver disease is a major cause of morbidity and mortality among human immunodeficiency virus (HIV)-infected persons. We evaluated the prevalence, etiology, and factors associated with liver dysfunction in patients during the highly active antiretroviral therapy era. METHODS: We performed liver tests (baseline and after a 6-month follow-up period) in HIV-infected patients treated at a large clinic. Comprehensive laboratory and ultrasound analyses were performed. Factors associated with liver test abnormalities were assessed using multivariate logistic regression models. RESULTS: Eighty of 299 HIV-positive patients (27%) had abnormal liver test results during the 6-month study period. The majority of abnormalities were grade 1. Of those with liver test abnormalities, the most common diagnosis was nonalcoholic fatty liver disease (30%), followed by excessive alcohol use (13%), chronic hepatitis B (9%), chronic active hepatitis C (5%), and other (hemochromatosis and autoimmune hepatitis, 2%); 8 participants (10%) had more than 1 diagnosis. In total, 39 HIV patients with abnormal liver test results (49%) had a defined underlying liver disease. Despite laboratory tests and ultrasound examination, 41 abnormal liver test results (51%) were unexplained. Multivariate analyses of this group found that increased total cholesterol levels (odds ratio, 1.6 per 40-mg/dL increase; P = .01) were associated with liver abnormalities. CONCLUSIONS: Liver test abnormalities are common among HIV patients during the highly active antiretroviral therapy era. The most common diagnosis was nonalcoholic fatty liver disease. Despite laboratory and radiologic investigations into the cause of liver dysfunction, 51% were unexplained, but might be related to unrecognized fatty liver disease. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS:Liver disease is a major cause of morbidity and mortality among humanimmunodeficiency virus (HIV)-infectedpersons. We evaluated the prevalence, etiology, and factors associated with liver dysfunction in patients during the highly active antiretroviral therapy era. METHODS: We performed liver tests (baseline and after a 6-month follow-up period) in HIV-infectedpatients treated at a large clinic. Comprehensive laboratory and ultrasound analyses were performed. Factors associated with liver test abnormalities were assessed using multivariate logistic regression models. RESULTS: Eighty of 299 HIV-positivepatients (27%) had abnormal liver test results during the 6-month study period. The majority of abnormalities were grade 1. Of those with liver test abnormalities, the most common diagnosis was nonalcoholic fatty liver disease (30%), followed by excessive alcohol use (13%), chronic hepatitis B (9%), chronic active hepatitis C (5%), and other (hemochromatosis and autoimmune hepatitis, 2%); 8 participants (10%) had more than 1 diagnosis. In total, 39 HIVpatients with abnormal liver test results (49%) had a defined underlying liver disease. Despite laboratory tests and ultrasound examination, 41 abnormal liver test results (51%) were unexplained. Multivariate analyses of this group found that increased total cholesterol levels (odds ratio, 1.6 per 40-mg/dL increase; P = .01) were associated with liver abnormalities. CONCLUSIONS:Liver test abnormalities are common among HIVpatients during the highly active antiretroviral therapy era. The most common diagnosis was nonalcoholic fatty liver disease. Despite laboratory and radiologic investigations into the cause of liver dysfunction, 51% were unexplained, but might be related to unrecognized fatty liver disease. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: M Puoti; A Spinetti; A Ghezzi; F Donato; S Zaltron; V Putzolu; E Quiros-Roldan; B Zanini; S Casari; G Carosi Journal: J Acquir Immune Defic Syndr Date: 2000-07-01 Impact factor: 3.731
Authors: Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: Caryn G Morse; Mary McLaughlin; Lindsay Matthews; Michael Proschan; Francine Thomas; Ahmed M Gharib; Mones Abu-Asab; Abigail Orenstein; Ronald E Engle; Xiaojun Hu; Richard Lempicki; Colleen Hadigan; David E Kleiner; Theo Heller; Joseph A Kovacs Journal: Clin Infect Dis Date: 2015-02-13 Impact factor: 9.079
Authors: Lindsay T Fourman; Natalia Czerwonka; Meghan N Feldpausch; Julian Weiss; Jean-Claude Mamputu; Julian Falutz; Josée Morin; Christian Marsolais; Takara L Stanley; Steven K Grinspoon Journal: AIDS Date: 2017-10-23 Impact factor: 4.177
Authors: Aman Sharma; Ravinder Kaur Sachdeva; Mahendra Kumar; Ritu Nehra; Monika Nakra; Deborah Jones Journal: J Int Assoc Provid AIDS Care Date: 2013-06-21
Authors: Susan E Buskin; Elizabeth A Barash; John D Scott; David M Aboulafia; Robert W Wood Journal: World J Gastroenterol Date: 2011-04-14 Impact factor: 5.742